Expression of Tumour-Associated MUC1 Is a Poor Prognostic Marker in Breast Cancer in Kumasi, Ghana

Abstract EN

Background.

Immunohistochemical assessment of breast cancer and stratification into the basic molecular subtypes afford a much deeper insight into the biology of breast cancer, while presenting with opportunities to exploit personalized, targeted treatment.

Traditionally, the oestrogen, progesterone, and epidermal growth factor receptors are assessed.

MUC1, a transmembrane mucin, has been demonstrated a potential prognostic and metastatic marker in breast cancer.

However, there have been a limited number of studies addressing the predictive and prognostic features of MUC1 in African breast cancer.

This study aims at addressing the expression profiles of MUC1 and other biomarkers in Ghanaian breast cancer and determines its predictive and prognostic characteristics, in relation to other clinicopathological features.

Methods.

Haematoxylin and eosin (H&E) slides of breast cancer cases were reviewed and 203 suitable cases were selected for tissue microarray (TMA) construction and immunohistochemistry.

Anti-ER, PR, HER2, Ki-67, and MUC1 antibodies were used.

Results from the immunostaining were analysed using SPSS version 23.

Results.

About 59% of cases expressed MUC1.

Majority of cases in the study showed a lack of expression of all three traditional markers (29% expressed ER, 10.9% PR, and 20.7% HER2).

Ki-67 index were 62.1% (low), 16.5% (moderate), and 21.4% (high).

MUC1 expressions among the molecular classes were luminal A (60.7%), luminal B (68.8%), HER2 overexpression (87.5%), and triple negative (56.6%).

There were significant associations between MUC1 and HER2 overexpression (p=0.01) and triple negative (p<0.01).

Conclusion.

The high proportion of breast cancer cases expressing MUC1, as well as its association with the two most aggressive molecular classes, indicate a substantial role in the biology of breast cancer in our cohort, and it is an indication of poor prognosis.